Literature DB >> 1861077

Effect of nephritogenic antibody on complement regulation in cultured rat glomerular epithelial cells.

R J Quigg1, A V Cybulsky, D J Salant.   

Abstract

In passive Heymann nephritis, a rat model of membranous nephropathy, antibody (anti-Fx1A) activates C on the surface of the glomerular epithelial cell (GEC), leading to GEC injury and proteinuria. In this study, we examined C activation by anti-Fx1A in cultured rat GEC. In addition to anti-Fx1A IgG, anti-Fx1A F(ab')2 and Fab' led to GEC injury in the presence of rat or human sera as sources of C. Cytotoxicity was Mg2+ and factor B dependent, but Ca2+ independent, indicating that anti-Fx1A activated the C alternative pathway (AP). Furthermore, in the presence of Mg2+ and factor B, anti-Fx1A enhanced 125I-C3b deposition on GEC in the absence of classical pathway activation. AP C3 and C5 convertases formed on GEC (GEC-C3bBbP) were inactivated over time, probably due to binding of GEC C regulatory proteins. This inactivation was prevented when GEC-C3bBbP were incubated with anti-Fx1A IgG. An antibody raised against cultured GEC that binds to GEC in vitro and in vivo had no effect on C3 and C5 convertases, suggesting that stabilization of C3bBbP is unique to anti-Fx1A. Anti-Fx1A Fab' also stabilized GEC-C3bBbP, indicating that cross-linking of membrane Ag was not required. C3bBbP on E were not affected by anti-Fx1A, excluding direct stabilization of convertases by anti-Fx1A. Therefore, anti-Fx1A inhibits C regulation on GEC, which can account for its ability to activate the AP. This represents a potentially powerful mechanism of producing disease in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1861077

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Inhibition of the alternative pathway of complement by glomerular chondroitin sulphate proteoglycan.

Authors:  R J Quigg
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

Review 2.  Complement regulation in renal disease models.

Authors:  Abhijit Naik; Shweta Sharma; Richard J Quigg
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

3.  Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis.

Authors:  M Schulze; C J Pruchno; M Burns; P J Baker; R J Johnson; W G Couser
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

4.  Generation of a novel decay accelerating factor (DAF) knock-out rat model using clustered regularly-interspaced short palindromic repeats, (CRISPR)/associated protein 9 (Cas9), genome editing.

Authors:  Maria G Detsika; K Goudevenou; A M Geurts; H Gakiopoulou; E Grapsa; Elias A Lianos
Journal:  Transgenic Res       Date:  2021-01-02       Impact factor: 2.788

5.  Inhibition of complement regulation is key to the pathogenesis of active Heymann nephritis.

Authors:  B Schiller; C He; D J Salant; A Lim; J J Alexander; R J Quigg
Journal:  J Exp Med       Date:  1998-10-05       Impact factor: 14.307

Review 6.  Alternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous Nephropathy.

Authors:  Dorin-Bogdan Borza
Journal:  Front Immunol       Date:  2016-04-25       Impact factor: 7.561

Review 7.  Therapeutic uses of recombinant complement protein inhibitors.

Authors:  K R Kalli; P Hsu; D T Fearon
Journal:  Springer Semin Immunopathol       Date:  1994
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.